** Shares of drugmaker Perrigo PRGO.N rise 20% to $28.98, highest in about three months
** Co says on an investor call that it will lay out plans to "consumerize, simplify and scale its global self-care platform"
** Expects 2025 adj profit of $2.90 to $3.10 per share, compared to analysts' estimate of $3.04 per share
** Sees 2025 net sales growth of 1% to 3%; organic compound annual sales growth of 2.5% to 4.5% for 2025 to 2027
** Co posted late on Thursday Q4 sales of $1.14 bln compared to analysts' estimate of $1.2 bln, according to data compiled by LSEG
** Co reported Q4 adj profit of 93 cents per share in line with estimates
** PRGO has fallen 25% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.